Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J To Persevere In ACS After Another “Complete Response” For Xarelto

This article was originally published in The Pink Sheet Daily

Executive Summary

J&J says it remains confident about getting expanded approval for Xarelto after receiving a “complete response” letter from FDA for reducing risk of stent thrombosis in patients with acute coronary syndrome.

You may also be interested in...

FDA Questions Evidence For Janssen’s Xarelto In Acute Coronary Syndrome

Although FDA suggested the sponsor consider a limited duration of use for rivaroxaban in the ACS setting, advisory committee briefing documents reflect doubts about the strength of analyses supporting such a claim.

FDA Panel To Take Second Look After J&J Plugged Holes In Xarelto ATLAS Data

Broader issue of missing data in clinical trials could see further discussion as FDA’s Cardiovascular and Renal Advisory Committee will relook at Xarelto’s acute coronary syndrome indication Jan. 16, now that J&J has tried to address the missing data that befuddled the committee on the first go-round.

TMI from TIMI: Xarelto and the Trouble with Very Large Trials

With bigger clinical trials come potentially bigger problems. That, at least, is what sponsors of 15,000-plus trials in cardiovascular medicine are finding out. J&J/Bayer’s experience in late May with Xarelto for acute coronary syndrome is a case in point—and it also provides timely context for the surprising setback for another CV project, Pfizer/BMS' Eliquis.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts